Asset profile
PF-00489791
Unknown / undisclosed
Evidence outlook · program status
Discontinued, for reasons the sponsor has not stated
PF-00489791 was Pfizer’s PDE5 inhibitor, studied in diabetic nephropathy, sickle cell disease and Raynaud’s. Pfizer’s own text on the terminated study NCT00853112 attributes the stop to a change in the compound’s development rather than to safety. The programme itself then ended: PF-00489791 is listed under Cardiovascular/Metabolics in the Pfizer pipeline filed with the SEC on 28 April 2014 (exhibit 99.6 to Pfizer’s 8-K, accession 0001193125-14-161303), no SEC filing has named it since May 2014, and Pfizer’s current pipeline page (pfizer.com/science/drug-product-pipeline, updated 4 August 2026) enumerates every investigational medicine by phase and therapy area without it. No reason for the programme stop is stated. The trials below are preserved as the program's evidence history; no evidence signal is assigned to a program the sponsor has stopped.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
No competitors sharing a mechanism or indication in the current universe.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.